FIELD: medicine, virology. SUBSTANCE: invention relates to the prophylaxis or inhibition of infection of T-lymphocytes with human immunodeficiency virus and virus replication in vivo. Method involves the use of 4-aminoquinolines at the dose 300-2000 mg for a week. EFFECT: enhanced quality of prophylaxis and treatment of infection. 6 cl
| Title | Year | Author | Number |
|---|---|---|---|
| SUBTYPE A TYPE 1 IV710 HUMAN IMMUNODEFICIENCY VIRAL STRAIN RESISTANT TO ANTIRETROVIRAL PREPARATIONS FOR DIAGNOSTIC AND VACCINE PREPARATIONS | 2012 |
|
RU2513692C1 |
| SUBTYPE B TYPE 1 IV735 HUMAN IMMUNODEFICIENCY VIRAL STRAIN FOR DIAGNOSTIC AND VACCINE PREPARATIONS | 2012 |
|
RU2520813C2 |
| LINEAR OR CYCLIC PEPTIDES, THEIR USING AND METHOD OF PATIENT TREATMENT | 1993 |
|
RU2130317C1 |
| HUMAN IMMUNODEFICIENCY VIRUS STRAIN TYPE 1 IV741 SUBTYPE AE FOR DIAGNOSTIC AND VACCINE PREPARATIONS | 2012 |
|
RU2520814C2 |
| METHOD FOR DIAGNOSING HIV | 1988 |
|
RU2049336C1 |
| METHOD OF ACTION ON DISEASE DEVELOPMENT CAUSED BY HIV-VIRUS OR VIRUS CAUSING SIMILAR BIOCHEMICAL OR CLINICAL PICTURE | 1988 |
|
RU2021810C1 |
| USE OF INACTIVATED INTACT VIRUS OF COMPATIBLE SUBTYPE TO OBTAIN ACELLULAR VACCINE AND METHOD OF TREATING HIV INFECTION | 2005 |
|
RU2396346C2 |
| VIRAL VECTORS WITH CONDITION-DEPENDENT REPLICATION AND THEIR USING | 2001 |
|
RU2301260C2 |
| PLASMID FOR EXPRESSION OF RETROVIRUS HIV-1 ANTI-MRNA (VARIANTS) | 1992 |
|
RU2135583C1 |
| QUINOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING VIRAL INFECTION | 2016 |
|
RU2723016C2 |
